Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
about
Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitisPromising biological therapies for ulcerative colitis: A review of the literatureNew Immunosuppressive Therapies in Uveitis TreatmentAnti-TNF therapy for juvenile idiopathic arthritis-related uveitisBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsMolecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseasesGolimumab for the treatment of ulcerative colitisTNF inhibitor therapy for rheumatoid arthritisInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.New treatments for ulcerative colitis: do we have pediatric data?Golimumab for the treatment of ulcerative colitis.Have we overestimated the benefit of human(ized) antibodies?Detection and characterization of subvisible aggregates of monoclonal IgG in serumRheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studyOne target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH studyEfficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.Effectiveness of golimumab in clinical management of patients with rheumatoid arthritisGolimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study throughClinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.Multivalent pIX phage display selects for distinct and improved antibody properties.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewRecent advances in managing and understanding uveitis.TNF inhibition for ophthalmic indications: current status and outlook.Investigational cytokine-targeted therapies for ulcerative colitis.Targeting TNF-α for the treatment of inflammatory bowel disease.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Vedolizumab for the treatment of ulcerative colitis.Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Necroinflammation in Kidney Disease.New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Golimumab for treatment of axial spondyloarthritis.
P2860
Q26764801-3D74FA99-1E58-490F-B75F-35096E0F337CQ26776139-7B3F2E9E-4756-47B1-99EC-5ADD76C1CFE4Q26798201-DD6BB306-D8E6-4802-846B-AF05201C60B3Q26849811-B6C3644C-5695-41FA-B466-ABC73D699053Q26999078-C674EBCB-6762-4DD2-A4AF-C8855A096330Q28067245-FC723EA4-3FAF-4587-8579-7F8C8C537680Q28236322-70E92EA7-EF0A-4A15-9EBA-E9B1B3E1F2B4Q28972424-6CE3F789-3ABD-4F7F-821E-189ACA268C24Q30240229-5540A04B-E178-4E31-BCD9-01EF0E1F4D2CQ31076366-0D0A37B9-E737-40CE-BEBB-010E4FF4789EQ33852257-B10D5282-005B-4EE8-B071-118DC0D78220Q34142714-155716F2-AA6D-4DB8-8109-D6578BD9A893Q34216430-136519AE-BB22-4F69-B22F-AC7FC2DC766EQ35544546-49D070DF-F465-462A-82AE-8036075637A8Q35569418-498B60C4-2254-409E-9CCD-6865E87F8522Q36023494-CA7F946E-CF2B-45D4-8C20-F2FF26AD641DQ36085461-11E2F91C-D251-4586-BB33-8C5D6B9A4349Q36767782-82A083F0-29DE-49BC-9B43-82AC9A19D806Q37130039-F6A84C79-24E9-4DB6-9965-33DD85560BB0Q37267600-72265804-7CA7-4E6F-A05D-77CB1FDB5781Q37501464-9F53CDC4-814B-458A-8FE8-5C4587A9ACFCQ37671983-70430B52-8799-42C4-98C4-77A2715668F3Q37709700-CB191270-08AB-4D5D-A6B6-8E7550B9D9F4Q38097327-45F3ECB8-D7C4-4430-922C-1E51D6C5C62AQ38117175-967CD7E4-5FAF-4928-B2B2-D11F5A933562Q38160905-527F2314-793C-4129-81EB-A668B23B2FE7Q38201788-2DFD74D4-8F31-4E06-8D0E-C374E7D7F3AAQ38209809-806161D1-B847-463C-96C5-966B4352AC81Q38239111-CD3E53A0-8DAF-419B-99EA-1D49C8183986Q38364465-2D04A100-9BFA-4E7E-AB1A-587D7FAC94BBQ38365049-E9C9202C-511B-48E9-A4DC-110E02C48748Q38365426-BA0E27CB-88BD-4669-9381-AD5A9013922DQ38579499-6C9C1424-A053-4C70-A945-9CBB20C1576EQ38582765-D9489F85-AE1A-4083-B998-67210321900BQ38591244-C657BC02-961E-4CD4-B03C-20761F1F5CCFQ38591272-0FFCE003-2D79-429F-8862-C2887F40F86BQ38592363-5905AD1B-1133-4756-B3B0-DE9562CCCCCEQ38645738-099E6EB5-91B9-4ACE-8175-D8BEDBDB3CC9Q38652276-DA014BC8-13E7-4A23-BD7D-9EEE7FAAEAB0Q38707718-ECEFAEF8-4007-4682-8E8D-2F811FD819C9
P2860
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Characterization of golimumab, ...... human tumor necrosis factor α.
@ast
Characterization of golimumab, ...... human tumor necrosis factor α.
@en
type
label
Characterization of golimumab, ...... human tumor necrosis factor α.
@ast
Characterization of golimumab, ...... human tumor necrosis factor α.
@en
prefLabel
Characterization of golimumab, ...... human tumor necrosis factor α.
@ast
Characterization of golimumab, ...... human tumor necrosis factor α.
@en
P2093
P2860
P356
P1476
Characterization of golimumab, ...... human tumor necrosis factor α.
@en
P2093
Audrey Baker
Bernard J Scallon
Bill Pikounis
David J Shealy
Eilyn R Lacy
Eva Emmell
George Gunn
Honghui Zhou
P2860
P304
P356
10.4161/MABS.12304
P577
2010-07-01T00:00:00Z